Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    CBRNE

    BARDA to Open New BAA for CBRN Medical Countermeasures

    By Stephanie LizotteFebruary 23, 2012
    Share
    Facebook LinkedIn Reddit Email

    Biomedical Advanced Research and Development Authority (BARDA) will release a new Broad Agency Announcment (BAA) on 4 March, 2012 for Advanced Research and Development of CBRN Medical Countermeasures.

    The purpose of the BAA is to solicit and fund proposals that focus on the following research areas in order to advance the knowledge and scientific understanding of selected candidates’ countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS):

    • Vaccines Development
    • Antitoxins and Therapeutics
    • Antimicrobials and Antivirals
    • Radiological and Nuclear Agent Countermeasures
    • Chemical Agent Countermeasures
    • Diagnostics

    BARDA, under the Department of Health and Human Services, encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).

    The solicitation number is BARDA-CBRN-BAA-12-100-SOL-00011 with details available here. It is anticipated that a pre-proposal conference will be held in late April, 2012 in the Washington D.C. area and possibly a opportuntity for organizations to participate by phone. Global Biodefense will publish further details as they become available.

    Antimicrobials Antitoxins Antivirals ASPR BAA BARDA HHS POC Diagnostics Strategic National Stockpile Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleMaking Existing Antibiotics More Effective Against Superbugs
    Next Article White Powder Letters Sent to U.S. Senate

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    SOREX Brings Top CBRNE Units to Dugway Proving Ground

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy